CGM BLE / IoT Connectivity Patent Landscape 2026
Dexcom dominates this highly concentrated field, holding the largest individual position among the top-ranked filers in CGM Bluetooth Low Energy and IoT connectivity. Annual filing volume peaked in 2021 and has since eased, signaling a field moving past its initial rapid-growth phase into a more selective, incremental-innovation mode.
Dexcom leads a tightly concentrated competitive field
Dexcom holds the top position in applicant rankings, followed by Ascensia Diabetes Care, Bigfoot Biomedical, Abbott Diabetes Care, and Tingo Medical. The field is highly concentrated: the top five filers account for 64% of the combined total of the hundred largest filers.
A pronounced tier gap separates the leader from the rest. Dexcom’s patent record count is more than three times that of the second-ranked applicant, Ascensia Diabetes Care, which itself substantially outpaces the third-ranked Bigfoot Biomedical. Abbott Diabetes Care and Tingo Medical occupy a distant fourth tier.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 57 | |
| 2 | Ascensia Diabetes Care Holdings AG | 17 | |
| 3 | Bigfoot Biomedical Inc | 14 | |
| 4 | Abbott Diabetes Care Inc | 6 | |
| 5 | Tingo Medical Ltd | 5 | |
| 6 | Animas Corporation | 5 | |
| 7 | General Motors LLC | 4 | |
| 8 | University of South Florida | 3 | |
| 9 | Medtronic MiniMed Inc | 2 | |
| 10 | Indian Institute of Technology Madras | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Roche Diabetes Care Inc | 2 | |
| 12 | MS RITU VERMA | 2 | |
| 13 | University of Padova | 2 | |
| 14 | Insulet Corporation | 2 | |
| 15 | MS SUPREET RUPAM | 1 | |
| 16 | SAVEETHA INST OF MEDICAL & TECH SCI | 1 | |
| 17 | Suzhou Herkang Medical Technology Co Ltd | 1 | |
| 18 | Manipal University Jaipur | 1 | |
| 19 | MR THEJA B C | 1 | |
| 20 | Ajay Kumar Garg Engineering College | 1 |
This steep concentration suggests that the foundational connectivity architecture — sensor-to-mobile communication, alert delivery, and healthcare informatics integration — is largely staked out by established diabetes-device incumbents, leaving limited room for undifferentiated entry into the core.
Filing counts for the most recent 18–24 months are subject to standard publication lag and likely understate actual activity; the 2025–2026 figures should be treated as preliminary. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2021; wireless and informatics branches dominate the mix
The annual filing trend and the IPC technology composition together reveal a field that burst to a peak around 2021 and has since moderated, with its technical footprint spanning clinical diagnostics, digital health informatics, and wireless protocol classes.
Annual filing trend
Filings rose sharply to a peak of 29 records in 2021, then retreated to single-digit or low-teen annual levels in subsequent years. The 2024 and 2026 figures are incomplete due to publication lag and should not be read as a structural further decline. The overall shape confirms the lifecycle characterization: a past-peak field with easing annual volume.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) is the dominant branch, reflecting CGM sensor and physiological-measurement patents at the core. G16H (Healthcare informatics) and G06F (Electric digital data processing) form a substantial second tier, covering app, platform, and UI logic. Wireless-specific branches — H04W (Wireless communication networks) and H04L (Digital information transmission) — are present but represent a smaller share, indicating that pure radio-protocol innovation is proportionally sparse relative to the clinical and informatics layers.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable continuous glucose monitor device
A continuous glucose monitor (CGM) sensor includes a glucose oxidation electrode and a counter electrode, and does not include a glucose-specific enzyme. The glucose oxidation electrode includes a nanoporous layer comprising metal nanoparticles. The CGM sensor generates an electrical signal indicative glucose oxidation in a liquid containing glucose, which… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Systems and methods for patient monitoring using a… | 172 |
| 2 | Method and system for closed-loop control of an ar… | 71 |
| 3 | Vehicle sharing accessory module and system | 36 |
| 4 | Method and device for processing glycemia level da… | 36 |
| 5 | Alarms and alerts for medication delivery devices … | 33 |
| 6 | Method and system for closed-loop control of an ar… | 29 |
| 7 | Systems and methods for patient monitoring using a… | 21 |
| 8 | Continuous glucose monitor communication with mult… | 18 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D strategy
Four structural observations — lifecycle stage, concentration, collaboration patterns, and geographic spread — frame the options available to R&D teams evaluating entry or expansion in CGM connectivity.
Post-peak field with selective incremental activity
The lifecycle stage is classified as Decline, driven by annual filings easing back from the 2021 peak. This does not mean the technology is obsolete, but it does indicate that broad platform patents are mostly filed, and new activity is increasingly targeted at specific subsystems or integration scenarios. R&D investment should focus on differentiated sub-problems rather than broad connectivity architectures.
Lifecycle: DeclineDominant leader with a steep drop-off to challengers
The top five filers hold 64% of the hundred largest filers’ combined total, with Dexcom alone representing the largest single block. Ascensia and Bigfoot hold meaningful but substantially smaller positions. This concentration implies that freedom-to-operate analysis is essential before entering the core sensor-communication and alert-management spaces, and that differentiation through adjacent technical routes is the more viable path for new entrants.
High concentrationOne confirmed co-filing pair: Dexcom and University of Padova
The evidence shows a single co-applicant relationship in this corpus: Dexcom and the University of Padova (Universita degli Studi di Padova), with one joint filing. Academic collaboration in this field is therefore rare and narrowly concentrated around the market leader. Research institutions and startups seeking industry partnership should note that Dexcom is the only incumbent currently demonstrating an open-innovation signal in this dataset.
Minimal collaborationUS-centric filing with selective international extension
The United States is the lead jurisdiction by a wide margin. Australia, Europe (EPO), and India each represent a secondary cluster, while WIPO PCT filings indicate selective global prosecution. Canada and Japan are present at lower volumes. China has minimal representation with only one patent record, which is notable given the scale of the Chinese digital-health and wearables market. This geographic gap may represent both a risk and an opportunity for applicants considering international portfolio expansion.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Dexcom Inc | University of Padova | 1 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom anchors the field; Bigfoot and Abbott are recent entrants with momentum
The applicant ranking is dominated by established diabetes-device companies, with Dexcom holding a position roughly three times larger than the next-ranked filer. Momentum data reveal diverging trajectories among the top five.
Dexcom Inc
Dexcom holds 57 patent records, the largest position in the ranking by a substantial margin. Its technical emphasis spans A61B 5 (clinical diagnosis and sensor measurement), G16H 40 (healthcare informatics and device management), and G06F 3 (human-computer interaction and UI), reflecting a full-stack connectivity strategy from sensor hardware through platform software. Recent momentum shows a decline of approximately 30% versus the prior period, consistent with the field’s post-peak lifecycle stage and likely reflecting a maturing portfolio rather than a strategic retreat.
patent records: 57Bigfoot Biomedical Inc
Bigfoot Biomedical holds 14 patent records and is classified as a new entrant in recent-period momentum, signaling that its filing activity in this specific connectivity corpus is a recent development. Its technical focus centers on A61B 5 (diagnosis and sensing), with secondary emphasis on A61M 5 (drug delivery devices) and G08B 21 (alarm and alert systems) — a profile consistent with closed-loop insulin delivery integration with CGM BLE signals. Abbott Diabetes Care similarly appears as a new entrant with 6 patent records, focused on A61B 5 and G16H healthcare informatics.
patent records: 14| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 16 | ▼ -30% |
| Ascensia Diabetes Care Holdings AG | 2 | ▼ -86% |
| Bigfoot Biomedical Inc | 3 | ▲ new entrant |
| Abbott Diabetes Care Inc | 1 | ▲ new entrant |
| University of Padova | 1 | ▲ new entrant |
Under-served branches in wireless protocols and display control
Several IPC branches within the corpus show relatively low patent record counts, indicating areas where the technical problems are real but the patent density is sparse. These observations do not confirm commercial opportunity without further technical and market validation.
H04W · Wireless communication networks
With 24 patent records, the wireless-network protocol branch is proportionally sparse given how central BLE is to CGM connectivity. Most incumbents claim at the A61B (sensor) and G16H (informatics) layers; the specific radio-layer optimizations — BLE channel management, coexistence with other IoT protocols, low-power pairing — remain under-patented. An entrant with RF or protocol expertise could find defensible space here, though freedom-to-operate review against H04W 4 and H04W 12 subclasses held by General Motors (which has four records in this branch) and others is warranted.
Search this in Eureka →H04L · Digital information transmission
H04L (Digital information transmission) has only 12 patent records in this corpus, suggesting that secure data transport — encryption, message integrity, and end-to-end communication architecture between CGM sensors and cloud platforms — is an under-patented sub-domain relative to its engineering importance. As regulatory pressure on medical-IoT cybersecurity increases, this branch could become more strategically significant. The sparse current count may reflect that incumbents have addressed this at the application layer (covered under G06F or G16H) rather than the transport layer, leaving a distinct filing angle available.
Search this in Eureka →How leaders differ across technology routes
Route coverage across the main technology branches in the current evidence set.
| Player | A61B 5 · Diagnosis & surgery | G16H 40 · Healthcare informatics | G16H 20 · Healthcare informatics | G06F 3 · Electric digital data processing | A61M 5 · Devices for body fluids |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 57 | Strong · 38 | Emerging · 7 | Moderate · 23 | Emerging · 4 |
| Animas Corporation | Strong · 5 | Strong · 5 | Strong · 5 | Absent | Strong · 5 |
| Ascensia Diabetes Care Holdings AG | Strong · 17 | Absent | Absent | Absent | Emerging · 2 |
| Bigfoot Biomedical Inc | Strong · 15 | Absent | Absent | Absent | Emerging · 2 |
| Abbott Diabetes Care Inc | Strong · 6 | Strong · 4 | Strong · 6 | Absent | Absent |
| Tingo Medical Ltd | Strong · 5 | Absent | Absent | Absent | Absent |
| MS RITU VERMA | Strong · 2 | Absent | Absent | Absent | Strong · 2 |
Frequently asked questions
The corpus covers 121 patent families in scope. The top applicant ranking is computed at the patent-record level, so record counts for individual filers reflect prosecution across multiple jurisdictions.
Dexcom Inc holds the top position with 57 patent records, more than three times the count of second-ranked Ascensia Diabetes Care Holdings AG (17 records). The top five filers together account for 64% of the combined total among the hundred largest filers.
Annual filing volume peaked in 2021 and has eased since then. The lifecycle stage is characterized as Decline based on this retreat from peak. Note that the most recent 18–24 months are subject to publication lag, so 2024–2026 figures are preliminary and likely understate true recent activity.
The United States is the lead jurisdiction. Australia, Europe (EPO), and India each form a secondary cluster. WIPO PCT filings indicate selective global prosecution. China has minimal representation with one patent record in this corpus.
The highest-cited work in the corpus covers patient monitoring systems and methods, with 172 forward citations. The second most-cited covers closed-loop control of artificial pancreas systems with 71 citations. These citation leaders concentrate in clinical-monitoring and closed-loop therapy domains rather than pure connectivity protocol patents.
Relative to the clinical and informatics branches, the wireless-protocol branch H04W (24 records) and the data-transmission branch H04L (12 records) are proportionally sparse. These cover radio-layer BLE optimization and secure transport architecture — areas of growing regulatory and engineering importance. Display control (G09G, 14 records) and specific-application computing (G16Z, 19 records) are also lower-density adjacent branches worth monitoring.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.